共 50 条
- [1] A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer (GC) that responded to platinum-based first-line chemotherapy.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)Ciardiello, FortunatoBang, Yung-JueBendell, Johanna C.Cervantes, AndresBrachmann, Rainer KarlZhang, YutingRaponi, MitchFarin, HeinrichLin, Shen
- [2] A phase 3, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Ciardiello, FortunatoBang, Yung-JueBendell, Johanna C.Cervantes, AndresBrachmann, Rainer KarlZhang, YutingRaponi, MitchFarin, HeinrichShen, Lin
- [3] A phase 3, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy - Trial in progressANNALS OF ONCOLOGY, 2018, 29Ciardiello, F.Bang, Y.Bendell, J.Cervantes, A.Brachmann, R.Zhang, Y.Raponi, M.Farin, H.Shen, L.
- [4] PARALLEL 303: Phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients (pts) with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line (1L) chemotherapy.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Ciardiello, FortunatoBang, Yung-JueBendell, Johanna C.Cervantes, AndresDvorkin, MikhailLopez, Charles D.Metges, Jean-PhilippeSanchez, AntonioCalvo, MarionaStrickland, AndrewKannourakis, GeorgeMuro, KeiKawakami, HisatoWei, JiaBorg, ChristopheMu, SongZhang, KathyZhang, MaggieShen, Lin
- [5] SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLCJOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)Cappuzzo, F.Ciuleanu, T.Stelmakh, L.Cicenas, S.Szczesna, A.Juhasz, E.Gonzalez, E. EstebanMolinier, O.Klingelschmitt, G.Giaccone, G.
- [6] Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study resultsCANCER MEDICINE, 2023, 12 (12): : 13145 - 13154Ciardiello, FortunatoBang, Yung-JueCervantes, AndresDvorkin, MikhailLopez, Charles D.Metges, Jean-PhilippeSanchez Ruiz, AntonioCalvo, MarionaStrickland, Andrew H.Kannourakis, GeorgeMuro, KeiKawakami, HisatoWei, JiaBorg, ChristopheZhu, ZhaoyinGupta, NealPelham, Robert J.Shen, Lin
- [7] Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III StudyJOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (30) : 3968 - 3976Ohtsu, AtsushiShah, Manish A.Van Cutsem, EricRha, Sun YoungSawaki, AkiraPark, Sook RyunLim, Ho YeongYamada, YasuhideWu, JianLanger, BerndStarnawski, MichalKang, Yoon-Koo
- [8] Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial CancerJOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (16) : 1797 - +Galsky, Matthew D.Mortazavi, AmirMilowsky, Matthew, IGeorge, SabyGupta, SumatiFleming, Mark T.Dang, Long H.Geynisman, Daniel M.Walling, RadhikaAlter, Robert S.Kassar, MohamadWang, JueGupta, ShilpaDavis, NancyPicus, JoelPhilips, GeorgeQuinn, David, IHaines, G. Kenneth, IIIHahn, Noah M.Zhao, QianqianYu, MenggangPal, Sumanta K.
- [9] Fuzuloparib as maintenance therapy among patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy: Results from a randomized, placebo-controlled, phase III trialGYNECOLOGIC ONCOLOGY, 2024, 190 : S74 - S75Wu, LingyingLi, NingWang, JingLi, QingshuiWang, DanboTang, JunyingZhang, CuiyingZhang, GuonanHao, MinYao, DeshengDuan, WeiGao, QingleiWang, LiZhang, YouzhongAn, RuifangYin, RutieZhou, QiYang, HongyingZhu, JianqingJiang, KuiWu, QiangZhao, WeidongHuang, YiXia, BairongYang, XinfengLi, Bo
- [10] A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY OF GEFITINIB (G) VERSUS PLACEBO (P) IN PATIENTS (PTS) WITH ADVANCED NSCLC, NON-PROGRESSING AFTER FIRST-LINE PLATINUM-BASED CHEMOTHERAPY (EORTC 08021-ILCP)ANNALS OF ONCOLOGY, 2010, 21 : 124 - 124Surmont, V. F.Gaafar, R. M.Scagliotti, G. V.van Klaveren, R. J.Papamichael, D.Hasan, B.Torri, V.van Meerbeeck, J. P.